Published in J Natl Cancer Inst Monogr on December 01, 2012
From evidence to best practice in laboratory medicine. Clin Biochem Rev (2013) 1.15
Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive meta-analysis. Epidemiol Health (2015) 1.01
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer (2014) 0.98
Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). Br J Cancer (2014) 0.96
A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urol (2014) 0.87
Increased Dietary Inflammatory Index (DII) Is Associated With Increased Risk of Prostate Cancer in Jamaican Men. Nutr Cancer (2015) 0.86
Prostate cancer mortality outcomes and patterns of primary treatment for Aboriginal men in New South Wales, Australia. BJU Int (2015) 0.83
Prostate cancer outcomes in France: treatments, adverse effects and two-year mortality. BMC Urol (2014) 0.80
A hospital-based study of initial observation for low-risk prostate cancer and its predictors in the United States. Can Urol Assoc J (2015) 0.78
Designing Normative Messages About Active Surveillance for Men With Localized Prostate Cancer. J Health Commun (2015) 0.77
American trends in expectant management utilization for prostate cancer from 2000 to 2009. Can Urol Assoc J (2014) 0.77
Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening. CMAJ Open (2016) 0.77
The increase in cancer prevalence and hospital burden in Western Australia, 1992-2011. Popul Health Metr (2014) 0.75
Spatial Genome Organization and Its Emerging Role as a Potential Diagnosis Tool. Front Genet (2016) 0.75
Long-term differences in urinary, bowel and sexual function among men treated with surgery versus radiation for prostate cancer. Asian J Androl (2013) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol (2009) 10.43
Overdiagnosis in cancer. J Natl Cancer Inst (2010) 10.31
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2011) 9.50
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med (1987) 6.41
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol (2011) 4.50
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 3.77
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst (2009) 2.85
Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol (2011) 2.53
Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol (2011) 2.51
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol (2009) 2.30
Comorbidity and competing risks for mortality in men with prostate cancer. Cancer (2011) 2.17
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol (2008) 2.02
Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol (2011) 1.83
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst (2000) 1.77
Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ (1998) 1.77
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. BJU Int (2006) 1.53
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol (1996) 1.46
Complexities of prostate-cancer risk. N Engl J Med (2008) 1.30
Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med (2009) 1.26
Active surveillance for prostate cancer: patient selection and management. Curr Oncol (2010) 1.22
Risk factors for prostate cancer. Rev Urol (2002) 1.21
Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol (2010) 1.18
A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer (2011) 1.17
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer (2007) 1.09
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int (2008) 1.07
Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study. Prostate (2006) 1.01
A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology (2006) 0.99
Populations at high risk for prostate cancer. Urol Clin North Am (2003) 0.98
Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU Int (2009) 0.96
Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int (2007) 0.96
Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol (2010) 0.88
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer (2009) 0.81
The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer. Int Urol Nephrol (2003) 0.79
Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. Eur Urol (2005) 0.78
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst (2006) 2.48
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol (2010) 2.33
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A (2009) 1.81
RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate (2007) 1.74
Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2013) 1.66
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev (2012) 1.63
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res (2005) 1.63
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med (2013) 1.60
The MAPP research network: design, patient characterization and operations. BMC Urol (2014) 1.56
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol (2014) 1.47
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology (2009) 1.45
Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology (2013) 1.45
Use of gelatin matrix to rapidly repair diaphragmatic injury during laparoscopy. Urology (2002) 1.45
Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol (2011) 1.44
Three-Dimensional (3D) Vision: Does It Improve Laparoscopic Skills? An Assessment of a 3D Head-Mounted Visualization System. Rev Urol (2005) 1.41
Pure laparoscopic radical heminephrectomy and partial isthmusectomy for renal cell carcinoma in a horseshoe kidney: case report and technical considerations. Urology (2005) 1.39
Benign prostatic hyperplasia: a progressive disease of aging men. Urology (2003) 1.31
Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev (2007) 1.30
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst (2010) 1.29
2D versus 3D visualization: impact on laparoscopic proficiency using the fundamentals of laparoscopic surgery skill set. J Laparoendosc Adv Surg Tech A (2012) 1.29
Laparoscopic partial nephrectomy for renal masses: effect of tumor location. Urology (2006) 1.27
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
Prostate cancer screening: current status and future perspectives. Nat Rev Urol (2010) 1.23
Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology (2007) 1.18
Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet (2011) 1.17
Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer (2008) 1.17
Screening for prostate cancer. BMJ (2010) 1.14
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int (2007) 1.13
Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control (2008) 1.13
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol (2011) 1.11
Prostate-specific antigen-based screening: controversy and guidelines. BMC Med (2015) 1.08
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology (2006) 1.07
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int (2008) 1.07
Polysymptomatic, polysyndromic presentation of patients with urological chronic pelvic pain syndrome. J Urol (2012) 1.04
Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol (2009) 1.03
Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr (2007) 1.02
Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet (2009) 1.01
The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int (2013) 1.01
Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev (2010) 0.99
Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology (2007) 0.98
Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia. J Urol (2012) 0.97
Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology (2004) 0.97
TNF polymorphisms and prostate cancer risk. Prostate (2008) 0.95
Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet (2011) 0.94
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology (2005) 0.93
Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol (2008) 0.93
Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs (2006) 0.93
Changes in symptoms during urologic chronic pelvic pain syndrome symptom flares: findings from one site of the MAPP Research Network. Neurourol Urodyn (2013) 0.92
Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis (2007) 0.90
Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. BJU Int (2014) 0.87
Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology (2003) 0.87
Renal hypothermia achieved by retrograde endoscopic cold saline perfusion: technique and initial clinical application. Urology (2003) 0.87
Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology (2011) 0.86
Managing the local complications of locally advanced prostate cancer. Curr Urol Rep (2007) 0.86
Ascertaining cause of death among men in the prostate cancer intervention versus observation trial. Clin Trials (2013) 0.85
5α-reductase inhibitors: preventing the treatable. Eur Urol (2012) 0.84
Prevention of benign prostatic hyperplasia disease. J Urol (2006) 0.84
Prostate cancer diagnosis. Mo Med (2010) 0.84
Laparoscopic partial nephrectomy with a novel electrosurgical snare in a porcine model. J Endourol (2002) 0.83
Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer (2002) 0.83
The effect of finasteride in men with benign prostatic hyperplasia. 1992. J Urol (2002) 0.83
Chemoprevention of prostate cancer. Annu Rev Med (2013) 0.83
Prostate cancer chemoprevention. Semin Oncol (2013) 0.83
Single-setting bilateral laparoscopic renal surgery: assessment of single-stage procedure. Urology (2005) 0.82
Prostate cancer: to screen or not to screen? Urol Clin North Am (2010) 0.80
Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy (2011) 0.79
High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? J Natl Cancer Inst (2007) 0.79
The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial. J Urol (2012) 0.79
The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. Urol Oncol (2012) 0.79
Laparoscopic prostatectomy for prostate cancer: continued role in urology. Surg Oncol Clin N Am (2012) 0.78
Prostate-specific antigen-based risk assessment in younger men. Eur Urol (2011) 0.78
Application of a fixed retractor system to facilitate laparoscopic radical prostatectomy. J Urol (2004) 0.78
Prospective randomized comparison of cutting and dilating disposable trocars for access during laparoscopic renal surgery. JSLS (2007) 0.77
Physical activity and benign prostatic hyperplasia-related outcomes and nocturia. Med Sci Sports Exerc (2015) 0.77